CA2529495C — Shunt for the treatment of glaucoma
Assigned to Individual · Expires 2013-02-05 · 13y expired
What this patent protects
A system is provided for reducing intraocular hypertension, the system comprising an implantable shunt, comprising a planar member having at least one microchannel disposed within the planar member. There is an inflow port disposed proximate to a first end of the microchannel and…
USPTO Abstract
A system is provided for reducing intraocular hypertension, the system comprising an implantable shunt, comprising a planar member having at least one microchannel disposed within the planar member. There is an inflow port disposed proximate to a first end of the microchannel and an outflow port disposed proximate to a second end of the microchannel, wherein the inflow port is configured such that when the implantable shunt is implanted, the inflow port is located about approximately within the region of an angle of an anterior chamber.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.